← Eichor
Study identifier: NCT07703722 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder

Condition: Major Depressive Disorder · Post-Traumatic Stress Disorder (PTSD)  ·  Sponsor: Khyber Medical University Peshawar

PhasePhase 3
Planned participants60
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersNo

About this study

Trauma-related Major Depressive Disorder (MDD) is frequently associated with poor response to conventional antidepressants, persistent psychological distress, and alterations in gut-brain axis function. Existing assessment tools primarily diagnose depression or PTSD but provide limited guidance for integrated clinical management. This study aims to develop and validate the Trauma Anxiety Depression Emotion (TADE) management tool while simultaneously evaluating the effectiveness of psilocybin-assisted Structured Integrated Reframing Therapy (SIRT) in improving clinical and biological outcomes. This prospective, four-arm randomized controlled trial will compare conventional therapy, psilocybin therapy, SIRT, and psilocybin-assisted SIRT. Participants will undergo assessment using the newly developed TADE tool together with established psychometric scales including HAM-D, PCL-5, and GAD-7. Biological outcomes will include serum gut-brain axis and inflammatory biomarkers, including Short-Chain Fatty Acids (SCFAs), Interleukin-6 (IL-6), Interleukin-10 (IL-10), Zonulin, Occludin, and Glial Cell Line-Derived Neurotrophic Factor (GDNF). Assessments will be performed at baseline, during treatment, and at 12-week follow-up. The study aims to determine whether combining psilocybin with SIRT provides superior clinical improvement and favorable biological changes compared with either intervention alone while establishing the validity and clinical utility of the TADE management tool.

This description comes directly from the study's public registry record.

Talk to the study team

Bushra Riaz, PhD*  ·  +92 3338000744  ·  bushrariaz098@gmail.com

Dr Owais Qaiser, PhD*  ·  +92 3139625788  ·  drowaisqaisar.ibms@kmu.edu.pk

Always discuss trial participation with your own doctor first.

Locations (3)

Institute of Health Science, Khyber Medical UniversityIslamabad, Capital, PakistanActive Not Recruiting
Hayatabad Medical Complex PeshawarPeshawar, KPK, PakistanRecruiting
Khyber Medical UniversityPeshawar, KPK, PakistanActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07703722